title: Antiretroviral drug treatment of CNS HIV-1 infection.
abstract: The advent of combination antiretroviral treatment has had a profound impact on CNS HIV infection and its clinical complications, but neurological impairment still occurs in patients on systemically effective combination therapy, and in some patients it may be important to consider antiretroviral drug entry and effects within the CNS. There are now data on the CNS exposure for most antiretroviral drugs. This review focuses on the CNS pharmacokinetics and pharmacodynamics of antiretroviral drugs in humans, and also discusses controversies in this field.
authors.affiliation: Institute of Biomedicine, Department of Infectious Diseases, University of Gothenburg, Smörslottsgatan 1, 416 85 Gothenburg, Sweden. aylin.yilmaz@gu.se
authors.forename: Aylin
authors.initials: A
authors.lastname: Yilmaz
authors.forename: Richard W
authors.initials: RW
authors.lastname: Price
authors.forename: Magnus
authors.initials: M
authors.lastname: Gisslén
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D018792:Encephalitis, Viral / Q000188:drug therapy* / Q000821:virology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents